Characterization of CD8⁺ T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL)

Table 2

Monitoring the fine specificity of the antigen-specific CD8⁺ T-cell responses in DTH skin biopsies and peripheral blood of melanoma patients.

Patient code	gp100		Tyrosinase		MAGE-C2		MAGE-A3
	DTH skin biopsy	Peripheral blood	DTH skin biopsy	Peripheral blood	DTH skin biopsy	Peripheral blood	DTH skin biopsy	Peripheral blood
88			87– 95^a	87– 95
				121–171
				161–211
89			121–171	385–403^*	281–331	375-371
92					41–91	41–91
					161–211	161–211
					241–291	241–291
					281–331
					321–371
113	81–95	33–47	201–215	201–215	285–299	165–179	65–79	77–91
	85–99	293–307	205–219	205–219	289–303	189–203	105–119	165–179
			209–223	413–427		241–291^*	113–127	169–183
			285–299			257–271	161–175	297–311
			309–323			285–299	165–179
			369–377			289–303	189–203
			433–447				193–207

^aNumbers indicate the amino acid numbers of the antigenic region recognized by the CD8⁺ T cells.
^*Indicates antigen-specific CD8⁺ T-cell responses that were already present before the DC treatment.
Bold numbers were antigenic regions recognized by CD8⁺ T cells in both skin and peripheral blood.